Media Release
Roche announces Brad Moore as president and CEO of Roche
Diagnostics North America
INDIANAPOLIS, December 5, 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today
announced the appointment of Brad Moore as president and CEO of Roche Diagnostics
North America, effective January 1, 2023. Moore currently serves as senior vice president,
Core Lab and Point of Care, within Roche Diagnostics North America.
Moore will succeed and report to Matt Sause, who was recently appointed CEO of Roche
Diagnostics globally, effective January 1, 2023. The position will continue to be based at
Roche Diagnostics’ North American headquarters in Indianapolis.
“Brad has a proven reputation for delivering outstanding results and is a highly effective
leader,” said Matt Sause, current president and CEO of Roche Diagnostics North America
and incumbent CEO of Roche Diagnostics. “I’m condent his experience will be a
tremendous asset for the North America team, our customers and our patients.”
Moore joined Roche in October 2016 as Head of North America Diabetes Care, leading
commercial operations for the U.S. and Canada. In 2019, the role expanded to include the
broader scope of Europe and North American commercial operations in mature markets in
Europe, the U.S., Canada, Australia and New Zealand within Roche Diabetes Care. In 2020,
Moore assumed his current position, leading the newly-created Core Lab and Point of Care
commercial business unit.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the rst industrial manufacturers of
branded medicines, Roche has grown into the world’s largest biotechnology company and
the global leader in in-vitro diagnostics. The company pursues scientic excellence to
discover and develop medicines and diagnostics for improving and saving the lives of people
around the world. We are a pioneer in personalized healthcare and want to further transform
how healthcare is delivered to have an even greater impact. To provide the best care for
each person we partner with many stakeholders and combine our strengths in Diagnostics
and Pharma with data insights from the clinical practice.
In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been
named one of the most sustainable companies in the pharmaceutical industry by the Dow
Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reects
our efforts to improve access to healthcare together with local partners in every country we
work.
